| No. |
Collaborators |
Retro Protocol ID |
Protocol title |
Site/Study type |
1 |
CDC-Thailand |
N/A |
HIV-1 Molecular Epidemiology in the Bangkok Men who have sex with Men (MSM) cohort study:CDC Protocol # 4614 sub study |
Laboratory study |
2 |
SEARCH |
N/A |
Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV |
Laboratory study |
3 |
THAI RED CROSS |
N/A |
Study of full-length and partial HIV genetic sequences in seroconverting blood donors collected during September 2007-March 2008 |
Laboratory study |
4 |
MOPH/
TAVEG |
RV144 |
A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX® B/E) Boosting in HIV-uninfected Thai Adults |
Phase III |
5 |
MOPH/TAVEG |
RV152 |
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who become HIV-1 infected during participation in a phase III vaccine trial of ALVAC-HIV and AIDSVAX® B/E |
Natural history |
6 |
MHRP
SIRIRAJ |
RV158 |
Phase I trial MVA-CMDR among HIV-negative adults |
Phase I |
7 |
RTA |
RV174 |
The Effect of the HLA B46+ Allele on the Natural History and Progression of HIV-1 Infections in Thailand |
Laboratory study |
8 |
MHRP |
RV209 |
Immunological assessment of RV135, A phase I/II of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen 120 B/E (AIDSVAX B/E) Boosting in Thai-Seronegative Adults, using recently validated immuno-monitoring assays |
Laboratory study |
9 |
THAI RED CROSS |
RV212 |
A cross-sectional study to screen for and generate broadly neutralizing monoclonal antibodies from HIV infected individuals |
Natural History |
10 |
RTA |
RV217d |
HIV-1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in a Cohort in Thailand |
High-risk Cohort
Acute HIV infection |
11 |
MHRP |
RV237 |
Development and Characterization of Reagents for Studies of HIV-1 Neutralization from Archived Cell and Plasma Samples |
Laboratory study |
12 |
SEARCH
PMK
Chulalongkorn |
RV238 |
HIV-1 Specific Immune Responses in Thai Individuals with HIV Dementia |
Laboratory Study |
13 |
AFRIMS |
RV243 |
Assessment of neutralizing antibody in participants from phase I/II Trials of ALVAC-HIV (vCP1521) priming with Chiron gp120 B/E, sanofi-pasteur oligomeric gp160, or AIDSVAX™ B/E gp120 B/E boosting against a newly developed, standardized panel of HIV-1 isolates |
Laboratory study |
14 |
THAI RED CROSS |
RV254 |
Establish and charaterize an acute HIV infection cohort in a Thai high risk population |
Therapeutic Cohort |
15 |
RTA |
RV262 |
Phase I Study of the Safety and Immunogenicity of PennVaxG DNA (Env (A, C, D) & consensus Gag) with IL-15 DNA Plasmid Adjuvant Administered by Intramuscular Biojector® 2000 Injection or by Intramuscular Electroporation using the CELLECTRA® Device Followed by MVA-CMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults |
Phase 1b |
16 |
AFRIMS |
RV269-006 |
To determine the concentration, characterization, and neutralizing activity of mucosal and plasma antibodies from RV118/HSRRB Log #A-7856" |
Laboratory study |
17 |
MHRP |
RV274 |
Specimen Collection Procedures for Clinical Laboratory Quality Management Practices |
Laboratory study |
18 |
AFRIMS |
TBD |
Characterization of humoral neutralizing activity in plasma of HIV individuals |
Laboratory study |
19 |
THAI RED CROSS |
RV304 |
Characteristics of immune cells in gut mucosa of HIV negative and chronically HIV-infected Thais |
Cohort study |
20 |
MOPH/
TAVEG |
RV305 |
Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV144: Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX® B/E) Boosting in HIV-uninfected Thai Adults |
Phase 2b
Follow on immunogenicity study |
21 |
TBD |
RV306 |
Randomized, Double Blind Evaluation of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming and Multiple Boosting Regimens with and without VaxGen gp120 B/E (AIDSVAX® B/E) in HIV-uninfected Thai Adults |
Phase 2b |
22 |
THAI RED CROSS
KAROLINSKA INSTITUTE |
RV310 |
RV254 patients on mega HAART getting MVA vaccine |
Therapeutic vaccine
Phase 1 |
23 |
AFRIMS |
|
Comparative Study of FcR-Mediated Antibody Effector Assays for HIV-1 (lab development in preparation for RV144 ADCC assays) |
Laboratory study |
